Glycogen synthase kinase 3β inhibitors prevent hepatitis C virus release/assembly through perturbation of lipid metabolism

Abstract Direct acting antivirals against hepatitis C virus (HCV) have markedly improved cure rates in the past few years. However, they are expensive, with only few targeting host cell factors, and affecting virus assembly and release. Huh7.5 cells infected with a JFH-1 clone of HCV were treated wi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mohammed A. Sarhan, Mohamed S. Abdel-Hakeem, Andrew L. Mason, D. Lorne Tyrrell, Michael Houghton
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
R
Q
Acceso en línea:https://doaj.org/article/f51753bd6d524097863f80264b9246e4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares